【佳学基因检测】Schlafen 家族是一种预后生物标志物，与胃癌的免疫浸润相对应

肿瘤基因检测费17800说明

开会学习医学博士年度肿瘤汇报《肿瘤基因易感位点列表及发生率分析》《Front Immunol》在. 2022 Aug 25;13:922138.发表了一篇题目为《Schlafen 家族是一种预后生物标志物，与胃癌的免疫浸润相对应》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Jiannan Xu, Songyao Chen, Jianming Liang, Tengfei Hao, Huabin Wang, Guangyao Liu, Xinghan Jin, Huan Li, Junchang Zhang, Changhua Zhang, Yulong He等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及精准治疗临床研究内容关键词：

SLFN 家族,舒拉芬,胃癌,预后生物标志物,肿瘤免疫细胞浸润

肿瘤靶向治疗基因检测临床应用结果

Schlafen (SLFN) 基因家族在免疫细胞分化和免疫调节中起重要作用。先前的研究发现，肠化生患者中 SLFN5 表达增加与胃癌 (GC) 进展相关。然而，尚未对 GC 中的 SLFN 家族进行调查。因此，我们系统地探讨了 SLFN 家族成员在 GC 患者中的表达和预后价值，阐明其可能的生物学功能及其与肿瘤免疫细胞浸润的相关性。 TCGA 数据库结果表明，SLFN5、SLFN11、SLFN12、SLFN12L 和 SLFN13 的表达在 GC 中显着升高。 UALCAN 和 KM 绘图仪数据库表明，增强的 SLFN 家族表达与淋巴结转移、肿瘤分期和肿瘤分级相关，并预测不良预后。 cBioportal 数据库显示 SLFN 家族在 GC 中具有高频率的遗传改变（约 12%），包括突变和扩增。 GeneMANIA 和 STRING 数据库确定了 20 个相互作用的基因和 16 个相互作用的蛋白质，它们是 SLFN 家族的潜在靶标。根据基因集富集分析 (GSEA) 和京都基因和基因组百科全书 (KEGG)，SLFN5、SLFN11、SLFN12、SLFN12L 和 SLFN14 可能与免疫反应有关。此外，Timer 和 TISIDB 数据库表明 SLFN5、SLFN11、SLFN12、SLFN12L 和 SLFN14 参与免疫反应。此外，Timer、TCGA 和 TISIDB 数据库表明，GC 中 SLFN5、SLFN11、SLFN12、SLFN12L 和 SLFN14 的表达与免疫细胞浸润水平、免疫检查点和许多免疫细胞标志物组的表达高度相关。我们分离了三份外周血单核细胞 (PBMC) 和活化的 T 细胞样本；结果表明，当T细胞活跃时，SLFN家族成员的表达明显下降。总之，SLFN 蛋白家族可作为 GC 的预后指标，并与 GC 中的免疫细胞浸润和免疫检查点表达有关。此外，它可能通过调节T细胞活化参与肿瘤免疫逃逸。舒拉芬；胃癌;预后生物标志物；肿瘤免疫细胞浸润

肿瘤发生与复发转移国际数据库描述：

The Schlafen (SLFN) gene family plays an important role in immune cell differentiation and immune regulation. Previous studies have found that the increased SLFN5 expression in patients with intestinal metaplasia correlates with gastric cancer (GC) progression. However, no investigation has been conducted on the SLFN family in GC. Therefore, we systematically explore the expression and prognostic value of SLFN family members in patients with GC, elucidating their possible biological function and its correlation with tumor immune cells infiltration. TCGA database results indicated that the SLFN5, SLFN11, SLFN12, SLFN12L, and SLFN13 expression was significantly higher in GC. The UALCAN and KM plotter databases indicated that enhanced the SLFN family expression was associated with lymph node metastasis, tumor stage, and tumor grade and predicted an adverse prognosis. cBioportal database revealed that the SLFN family had a high frequency of genetic alterations in GC (about 12%), including mutations and amplification. The GeneMANIA and STRING databases identified 20 interacting genes and 16 interacting proteins that act as potential targets of the SLFN family. SLFN5, SLFN11, SLFN12, SLFN12L, and SLFN14 may be implicated in the immunological response, according to Gene Set Enrichment Analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Additionally, Timer and TISIDB databases indicate that SLFN5, SLFN11, SLFN12, SLFN12L, and SLFN14 are involved in the immune response. Furthermore, Timer, TCGA, and TISIDB databases suggested that the SLFN5, SLFN11, SLFN12, SLFN12L, and SLFN14 expression in GC is highly linked with immune cell infiltration levels, immune checkpoint, and the many immune cell marker sets expression. We isolated three samples of peripheral blood mononuclear cell (PBMC) and activated T cells; the results showed the expression of SLFN family members decreased significantly when T cell active. In conclusion, the SLFN family of proteins may act as a prognostic indicator of GC and is associated with immune cell infiltration and immune checkpoint expression in GC. Additionally, it may be involved in tumor immune evasion by regulating T cell activation.Keywords: SLFN family; Schlafen; gastric cancer; prognostic biomarker; tumor immune cell infiltration